Current Molecular Medicine

Papers
(The H4-Index of Current Molecular Medicine is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
NF-κB1 Intronic Region Polymorphisms as Risk Factor for Head and Neck Cancer in HPV-Infected Population from Pakistan133
USP3 inhibition is Active Against Chemo-resistant Hepatocellular Carcinoma Anchorage-independent Growth via Suppressing Wnt/β-catenin40
Pre-clinical Efficacy and Safety Pharmacology of PEGylated Recombinant Human Endostatin32
Intracellular Ellagic Acid Derived from Goat Urine DMSO Fraction (GUDF) Predicted as an Inhibitor of c-Raf Kinase31
Attenuation of NLRP3 Inflammasome by Cigarette Smoke is Correlated with Decreased Defense Response of Oral Epithelial Cells to Candida albicans29
In Transfusion-Dependent Thalassemia Children, Increased Iron Overload is Associated with Lower Serum Alpha-Klotho, Which is Strongly Associated with Lower Total and Ionized Calcium Concentrations27
Altered Expression of TRIM Proteins - Inimical Outcome and Inimitable Oncogenic Function in Breast Cancer with Diverse Carcinogenic Hallmarks26
Transcription Factors in Deriving β Cell Regeneration: A Potential Novel Therapeutic Target24
Aberrant β-catenin Activity in Hepatoid Adenocarcinoma of the Stomach22
Free Radicals and Oxidative Stress: Signaling Mechanisms, Redox Basis for Human Diseases, and Cell Cycle Regulation21
Epigenetic Mechanisms of Antibiotic Resistance18
Ferroptosis and Cancer Immunotherapy17
Sodium Butyrate Pre-Treatment Enhance Differentiation of Bone Marrow Mesenchymal Stem Cells (BM-MSCs) into Hepatocytes and Improve Liver Injury17
Human Recombinant Relaxin (Serelaxin) as Anti-fibrotic Agent: Pharmacology, Limitations and Actual Perspectives17
COL12A1 Promotes Osteosarcoma Progression via the FAK/PI3K/AKT/mTOR Pathway16
NLRP3 Inflammasome Triggers Inflammation of Obstructive Sleep Apnea15
CRISPR-Cas9: A Potent Gene-editing Tool for the Treatment of Cancer15
0.072911977767944